Pap Smear miR-92a-5p and miR-155-5p as potential diagnostic biomarkers of squamous intraepithelial cervical cancer.
Biomarker
HPV E6/E7
HSIL
LSIL
miRNAs
Journal
Asian Pacific journal of cancer prevention : APJCP
ISSN: 2476-762X
Titre abrégé: Asian Pac J Cancer Prev
Pays: Thailand
ID NLM: 101130625
Informations de publication
Date de publication:
01 Apr 2021
01 Apr 2021
Historique:
received:
20
01
2021
entrez:
28
4
2021
pubmed:
29
4
2021
medline:
24
11
2021
Statut:
epublish
Résumé
one of the female-specific diseases with a high incidence and mortality is cervical cancer. The main cause of cervical cancer is infection with Human papilloma virus (HPV). Low-grade squamous intraepithelial lesions (LSIL) and High-grade squamous intraepithelial lesions (HSIL) usually is caused by an HPV infection. Considering the role of microRNAs (miRNAs) as diagnostic biomarkers for a variety of cancers, the aim of this study was to determine miR-92a-5p and miR-155-5p expression levels in LSIL and HSIL Pap Smear samples. After initial bioinformatic studies, A total of 75 samples (25 samples of patients with LSIL, 25 patients with HSIL and 25 healthy individuals) were subjected to RNA extraction and cDNA synthesis. The expressions levels of confirmed miRNAs in samples of patients with LSIL, HSIL and healthy individuals were evaluated by Real time PCR analysis. To demonstration the role of predicted miRNAs as novel biomarkers in diagnosis of LSIL and HSIL, ROC curve analysis was done. Bioinformatics results showed that miR-92a-5p and miR-155-5p target the HPV E6 and E7 genes. The expression levels of these miRNAs were strikingly higher in Pap smear of patients with LSIL than in the healthy individuals (35.36, P = 0.001) (62.23, P = 0.001). Similarity, expression levels of miR-92a-5p and miR-155-5p were amazingly higher in patients with HSIL than in the healthy individuals (33.62, P= 0.001) (69.07, P= 0.001). Although, the levels of miR-92a-5p (0.95, P = 0. 85) and miR-155-5p (1.11, P = 0.84) exhibited no statistical differences between patients with LSIL and HSIL. Also, ROC curve analyses verified that miR-92a-5p and miR-155-5p are specific and sensitive and may serve as new biomarkers for the early detection of cervical cancer. These data suggest miR-92a-5p and miR-155-5p, which are upregulated in LSIL and HSIL, can be consider as predictive biomarkers for the prognosis of cervical cancer patients.<br />.
Sections du résumé
BACKGROUND
BACKGROUND
one of the female-specific diseases with a high incidence and mortality is cervical cancer. The main cause of cervical cancer is infection with Human papilloma virus (HPV). Low-grade squamous intraepithelial lesions (LSIL) and High-grade squamous intraepithelial lesions (HSIL) usually is caused by an HPV infection. Considering the role of microRNAs (miRNAs) as diagnostic biomarkers for a variety of cancers, the aim of this study was to determine miR-92a-5p and miR-155-5p expression levels in LSIL and HSIL Pap Smear samples.
METHODS
METHODS
After initial bioinformatic studies, A total of 75 samples (25 samples of patients with LSIL, 25 patients with HSIL and 25 healthy individuals) were subjected to RNA extraction and cDNA synthesis. The expressions levels of confirmed miRNAs in samples of patients with LSIL, HSIL and healthy individuals were evaluated by Real time PCR analysis. To demonstration the role of predicted miRNAs as novel biomarkers in diagnosis of LSIL and HSIL, ROC curve analysis was done.
RESULTS
RESULTS
Bioinformatics results showed that miR-92a-5p and miR-155-5p target the HPV E6 and E7 genes. The expression levels of these miRNAs were strikingly higher in Pap smear of patients with LSIL than in the healthy individuals (35.36, P = 0.001) (62.23, P = 0.001). Similarity, expression levels of miR-92a-5p and miR-155-5p were amazingly higher in patients with HSIL than in the healthy individuals (33.62, P= 0.001) (69.07, P= 0.001). Although, the levels of miR-92a-5p (0.95, P = 0. 85) and miR-155-5p (1.11, P = 0.84) exhibited no statistical differences between patients with LSIL and HSIL. Also, ROC curve analyses verified that miR-92a-5p and miR-155-5p are specific and sensitive and may serve as new biomarkers for the early detection of cervical cancer.
CONCLUSION
CONCLUSIONS
These data suggest miR-92a-5p and miR-155-5p, which are upregulated in LSIL and HSIL, can be consider as predictive biomarkers for the prognosis of cervical cancer patients.<br />.
Identifiants
pubmed: 33906322
doi: 10.31557/APJCP.2021.22.4.1271
pmc: PMC8325111
pii:
doi:
Substances chimiques
MIRN155 microRNA, human
0
MIRN92 microRNA, human
0
MicroRNAs
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1271-1277Références
J Natl Cancer Inst. 2014 Sep 04;106(9):
pubmed: 25190727
Mol Carcinog. 2019 Aug;58(8):1338-1348
pubmed: 30997723
Proc Natl Acad Sci U S A. 2014 Mar 18;111(11):4262-7
pubmed: 24591631
Cancer Cell Int. 2017 Jun 9;17:63
pubmed: 28615991
Biomed Res Int. 2015;2015:304584
pubmed: 26180794
Maedica (Bucur). 2016 Mar;11(1):48-54
pubmed: 28465751
Mol Cancer. 2019 Apr 2;18(1):76
pubmed: 30940131
ScientificWorldJournal. 2014 Jan 02;2014:178075
pubmed: 24516357
Nat Chem Biol. 2007 Mar;3(3):166-73
pubmed: 17259978
Oncol Lett. 2017 Jul;14(1):767-775
pubmed: 28693232
Anticancer Res. 2015 Jan;35(1):523-30
pubmed: 25550598
Transpl Int. 2015 May;28(5):594-603
pubmed: 25703481
Nucleic Acids Res. 2002 May 1;30(9):e36
pubmed: 11972351
Biosci Rep. 2019 Apr 26;39(4):
pubmed: 30926679
Proc Natl Acad Sci U S A. 2008 Feb 5;105(5):1608-13
pubmed: 18227514
Mol Cancer. 2015 Feb 07;14:34
pubmed: 25743773
Case Rep Obstet Gynecol. 2016;2016:5857370
pubmed: 27830099
Nat Rev Cancer. 2006 Apr;6(4):259-69
pubmed: 16557279
Pathol Res Pract. 2018 Mar;214(3):374-379
pubmed: 29487007
Discov Med. 2012 Aug;14(75):125-31
pubmed: 22935209
PLoS One. 2018 Oct 29;13(10):e0205518
pubmed: 30372446
BMC Cancer. 2017 Sep 21;17(1):658
pubmed: 28934937
Oncol Res. 2017 Jan 2;25(1):137-145
pubmed: 28081742
J BUON. 2016 Mar-Apr;21(2):320-5
pubmed: 27273940
Cancer Cell Int. 2014 Aug 22;14:81
pubmed: 25788864
Biochem Biophys Res Commun. 2015 Feb 27;458(1):63-9
pubmed: 25623537
Int J Mol Sci. 2018 Feb 03;19(2):
pubmed: 29401683
Cell Physiol Biochem. 2018;50(4):1398-1413
pubmed: 30355924
Ann Oncol. 2011 Dec;22(12):2675-2686
pubmed: 21471563
Cancer Res. 2010 Feb 15;70(4):1441-8
pubmed: 20124485
PLoS Pathog. 2015 Mar 11;11(3):e1004712
pubmed: 25760330
Lancet. 2020 Feb 22;395(10224):591-603
pubmed: 32007142
Onco Targets Ther. 2019 Apr 29;12:3181-3196
pubmed: 31118671
Oncol Lett. 2019 Mar;17(3):3387-3391
pubmed: 30867774
Zhongguo Dang Dai Er Ke Za Zhi. 2017 Jul;19(7):776-780
pubmed: 28697830
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
JAMA. 2002 Apr 24;287(16):2114-9
pubmed: 11966386